



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/396, 31/351, A61P 35/00, A61K 31/352 // (A61K 31/396, 31:352) (A61K 31/396, 31:351) (A61K 31/352, 31:351) (A61K 31/351, 31:351)		A1	(11) International Publication Number: WO 00/50032 (43) International Publication Date: 31 August 2000 (31.08.00)
<p>(21) International Application Number: PCT/EP00/00745</p> <p>(22) International Filing Date: 31 January 2000 (31.01.00)</p> <p>(30) Priority Data: 9904387.9 25 February 1999 (25.02.99) GB</p> <p>(71) Applicant (<i>for all designated States except US</i>): PHARMACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milan (IT).</p> <p>(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): GERONI, Cristina [IT/IT]; Via Correggio, 48, I-20149 Milan (IT). RIPAMONTI, Marina [IT/IT]; Viale Fulvio Testi, 91, I-20162 Milan (IT). CARUSO, Michele [IT/IT]; Via Desiderio, 3, I-20131 Milan (IT). SUARATO, Antonino [IT/IT]; Via Degli Imbriani, 39, I-20158 Milan (IT).</p> <p>(74) Common Representative: PHARMACIA & UPJOHN S.P.A.; Viale Pasteur, 10, I-20014 Nerviano (IT).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: ANTITUMOUR SYNERGISTIC COMPOSITION</p> <p>(57) Abstract</p> <p>There are provided the combined use of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methansulfonyl daunorubicin or 4-demethoxy-N,N-bis(2-chloroethyl)-4'-methansulfonyl daunorubicin and an antineoplastic topoisomerase II inhibitor in the treatment of tumors and the use of said combination in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis.</p>			